Combination of sorafenib and everolimus regresses pancreatic neuroendocrine tumour significantly in vitro and vivo

#4316

Introduction: PNET is a rare group of highly heterogeneous tumours with neuroendocrine differentiation properties. Everolimus is the most promising drug for progressive well-differentiated pNETs. Sorafenib's anti-tumour activity may involve regulation of the mTOR pathway.

Aim(s): To investigate the effects of drug combination of sorafenib and everolimus on the proliferation of pNET cells and the expression level of mTOR.

Materials and methods: PNET cells（QGP-1 and Bon-1 cells）were collected from routine culture in vitro and then treated with different concentrations of sorafenib, everolimus and dual-drug combination applications for 24h. The ability of drugs to regulate tumours was further assessed by CCK-8, cloning, EDU assay and xenograft tumour model analysis. Western Blot was used to detect the level of mTOR in pNETs cells.

Conference:

Presenting Author: Zheng H

Authors: Zheng H,

Keywords: sorafenib, everolimus, pancreatic neuroendocrine tumour, mTOR,